← Back to Search

Behavioral Intervention

Intervention for Cardiovascular Disease (GRACE Trial)

N/A

Waitlist Available

Led By Lori Orlando, MD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 years or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at study completion, expected 1 year from study start

Awards & highlights

GRACE Trial Summary

This trial aims to develop a program called "GRACE" to help assess and manage health risks in populations with limited resources. The goal is to improve health outcomes, quality of life, and reduce costs

Who is the study for?

The GRACE trial is for patients with conditions like hyperthermia, liver disease, cardiovascular disease, cancer, or risk of heat stroke. It's also for their healthcare providers and family members who might have genetic risks. Participants should be willing to use a web-based platform to enter health history and may need to undergo genetic testing if advised.Check my eligibility

What is being tested?

GRACE aims to develop a framework for genomic medicine risk assessment that can work even in low-resource settings. The study will test how well this approach helps people understand their health risks based on genetics and improve patient outcomes through better-informed guidelines.See study design

What are the potential side effects?

Since the intervention involves risk assessment rather than medication or procedures, traditional side effects are not expected. However, participants may experience stress or anxiety from learning about their genetic risks.

GRACE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

GRACE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at study completion, expected 1 year from study start

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at study completion, expected 1 year from study start

This trial's timeline: 3 weeks for screening, Varies for treatment, and at study completion, expected 1 year from study start for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reach of genomic risk assessment

Uptake of genetic counseling risk recommendations by the participant

Uptake of genetic testing recommendations by the provider

+1 more

GRACE Trial Design

1Treatment groups

Experimental Treatment

Group I: InterventionExperimental Treatment1 Intervention

Risk assessment pipeline

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor

2,365 Previous Clinical Trials

3,419,890 Total Patients Enrolled

National Human Genome Research Institute (NHGRI)NIH

263 Previous Clinical Trials

283,382 Total Patients Enrolled

Lori Orlando, MDPrincipal InvestigatorDuke University

2 Previous Clinical Trials

3,620 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical study currently open to new participants?

"Data from clinicaltrials.gov indicates that the trial is not presently open for enrollment. Despite being listed on 2/1/2024 and last updated on 2/19/2024, it is temporarily closed to new participants. However, there are currently 1289 other ongoing trials actively seeking eligible individuals for participation at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase

2024. "Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06278883.

All > Liver Disease